#CancerAdvocacy #PatientVoices #HTA #tarlatamab #PatientExperience #CancerSupport #Imdelltra #SmallCellLungCancer #SCLC #PatientAdvocacy #CaregiverSupport #CancerAwareness #PublicFunding #AccessToCare #LungCancerCanada

タラタマブ（Imdelltra）、再発小細胞肺がんでFDA完全承認｜生存期間を5.3か月延長 | STELLANEWS.LIFE Amgenのタラタマブ（Imdelltra）が、広範期小細胞肺がんに対する第3相試験で全生存期間を有意に延長し、FDAの完全承認を取得。DLL3標的の二重特異性抗体として新たな治療選択肢に。

FDA grants full approval to Amgen’s Imdelltra (tarlatamab) for relapsed extensive-stage small cell lung cancer (ES-SCLC).

🔗 Full article: stellanews.life/technology_c...

#Imdelltra #Tarlatamab #Amgen #SCLC #Oncology #DLL3 #FDAApproval #Immunotherapy #ClinicalTrials

【タラタマブ（Imdelltra）、再発小細胞肺がんでFDA完全承認】
アムジェンのDLL3標的二重特異性T細胞誘導抗体タラタマブ（Imdelltra）が、
広範期小細胞肺がん（ES-SCLC）を対象にFDAの完全承認を取得。

#タラタマブ #Imdelltra #小細胞肺がん #Amgen #DLL3 #二重特異性抗体 #FDA承認 #DeLLphi304 #免疫療法

FDA Approves IMDELLTRA® as Standard Therapy for Small Cell Lung Cancer Amgen's IMDELLTRA® has received full FDA approval for treating extensive stage small cell lung cancer, significantly improving survival rates.

FDA Approves IMDELLTRA® as Standard Therapy for Small Cell Lung Cancer #Amgen #Thousand_Oaks #SCLC #IMDELLTRA

Amgen Reports Strong Financial Performance for Q1 2025 Driven by Global Product Demand and New Launches Amgen has announced impressive financial results for the first quarter of 2025, with strong demand for products and successful new launches driving growth.

Amgen Reports Strong Financial Performance for Q1 2025 Driven by Global Product Demand and New Launches #None #Amgen #Repatha #IMDELLTRA

IMDELLTRA® Shows Significant Survival Advantage for Small Cell Lung Cancer Patients Amgen's IMDELLTRA® demonstrates notable effectiveness in improving overall survival in small cell lung cancer patients in a Phase 3 trial, outperforming standard chemotherapy.

IMDELLTRA® Shows Significant Survival Advantage for Small Cell Lung Cancer Patients #USA #Amgen #Thousand_Oaks #SCLC #IMDELLTRA